Table 1 Characteristics of the 200 kidney transplant recipients before admission in ICU
Characteristics | Total N = 200 | Survivors N = 160 | In-hospital death N = 40 | p |
|---|---|---|---|---|
Age (n, %) | 61 [51–68] | 60 [49–66] | 65 [58–70] | 0.07 |
Male gender (n, %) | 126 (63) | 97 (60.6) | 29 (72.5) | 0.20 |
Comorbidities (n, %) | ||||
Diabetes mellitus | 71 (35.5) | 56 (35) | 15 (37.5) | 0.81 |
Heart disease (left ventricular systolic function < 45%) | 97 (48.5) | 73 (45.5) | 24 (60) | 0.11 |
Peripheral arterial disease | 23 (11.5) | 60 (37.5) | 24 (60) | 0.01 |
Solid cancer | 11 (5.5) | 6 (3.8) | 5 (12.5) | 0.05 |
Active hematological malignancy | 9 (4.5) | 6 (3.8) | 3 (7.5) | 1.00 |
Transplantation characteristics (n, %) | ||||
Deceased donor | 15 (7.5) | 14 (8.7) | 1 (2.5) | 0.31 |
First kidney transplantation | 166 (83) | 136 (85) | 30 (75) | 0.20 |
Induction | ||||
No | 30 (15) | 23 (14.4) | 7 (17.5) | 0.62 |
Polyclonal antibodies | 90 (45) | 74 (46.3) | 16 (40) | 0.58 |
IL2R blocking agents | 72 (36) | 57 (35.6) | 15 (37.5) | 0.85 |
Immunosuppressive regimen | ||||
Steroids | 184 (92) | 148 (92.5) | 36 (90) | 1.00 |
CNI | 161 (80.5) | 131 (81.8) | 30 (75) | 0.49 |
Tacrolimus | 123 (61.5) | 104 (65) | 19 (4.8) | 0.97 |
Antimetabolites | 163 (81.5) | 137 (85.6) | 26 (65) | 0.008 |
MMF | ||||
mTOR inhibitors | 36 (18) | 29 (18.1) | 7 (17.5) | 1.00 |
Belatacept | 8 (4) | 6 (3.8) | 2 (5) | 0.65 |
CNI, MPA, Steroids association | xx | xx | xx | |
History of acute rejection | ||||
Antibody mediated rejection | 26 (13) | 19 (11.8) | 7 (17.5) | 0.43 |
T-cell mediated rejection | 34 (17) | 28 (17.5) | 6 (15) | 0.82 |
Viral status before the admission # (n, %) | ||||
Blood Cytomegalovirus detection (n = 142) | 16 (11.3) | 9/107 (8.4) | 7/35 (20) | 0.07 |
Blood Epstein-Barr virus detection (n = 127) | 39 (30.7) | 24/96 (25) | 15/31 (48) | 0.02 |
Urine BK virus shedding (n = 115) | 28 (24.3) | 18/90 (20) | 10/25 (40) | 0.04 |
Immunological status before the admission in ICU (n, %) | ||||
Anti-HLA immunization (n = 188) | 71 (38) | 59/152 (38) | 12/36 (33) | 0.57 |
Donor-specific antibodies | 23 (12.2) | 19 (12.5) | 4 (11.1) | 1.00 |